- published: 31 Dec 2014
- views: 2572
Darifenacin (trade name Enablex in US and Canada, Emselex in Europe) is a medication used to treat urinary incontinence. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and previously was marketed by Novartis; however in 2010 US rights for were sold to Warner Chilcott for 400 million US$.
Darifenacin works by blocking the M3muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
It should not be used in people with urinary retention. Anticholinergic agents, such as darifenacin, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment.
Overactive Bladder Medications | Proven Way to Treat Overactive Bladder
Fesoterodine vs tolterodine in men and women with OAB
Pharmacology -ANTICHOLINERGIC DRUGS & NEUROMUSCULAR BLOCKING AGENTS (MADE EASY)
Drugs That May Cause Memory Loss
How to Pronounce Mecamylamine
How to Pronounce Amiloride hydrochloride
How to Pronounce Celiprolol
Mirabegron Market Strategies & Detailed Analysis